Your browser doesn't support javascript.
loading
Toxicity of JQ1 in neuronal derivatives of human umbilical cord mesenchymal stem cells.
Bakshi, Shreeya; McKee, Christina; Walker, Keegan; Brown, Christina; Chaudhry, G Rasul.
Afiliação
  • Bakshi S; Department of Biological Sciences, Oakland University, Rochester, MI 48309, USA.
  • McKee C; OU-WB Institute for Stem Cell and Regenerative Medicine, Oakland University, Rochester, MI 48309, USA.
  • Walker K; Department of Biological Sciences, Oakland University, Rochester, MI 48309, USA.
  • Brown C; OU-WB Institute for Stem Cell and Regenerative Medicine, Oakland University, Rochester, MI 48309, USA.
  • Chaudhry GR; Department of Biological Sciences, Oakland University, Rochester, MI 48309, USA.
Oncotarget ; 9(73): 33853-33864, 2018 Sep 18.
Article em En | MEDLINE | ID: mdl-30333915
Bromodomain and extra-terminal domain (BET) proteins regulate the transcription of many genes including c-MYC, a proto-oncogene, which is upregulated in many types of cancers. The thienodiazepine class of BET inhibitors, such as JQ1, inhibits growth of cancer cells and triggers apoptosis. However, the effects of BET inhibitors on normal cells and mesenchymal stem cells (MSCs), which are important in routine maintenance or regeneration of damaged cells and tissues, are poorly investigated. Previously, we have shown that JQ1 causes human umbilical cord MSCs to undergo cell cycle arrest and neural differentiation. In this study, we determined that JQ1 is more deleterious to neuronal derivatives (NDs) than adipogenic, chondrogenic or osteogenic derivatives of MSCs. NDs treated with JQ1 showed a significant decrease in cell proliferation, viability, and neuronal markers. JQ1 caused cell death through the intrinsic apoptotic pathway in NDs as determined by activation of Caspase 9 and increased expression of Cytochrome C. A comparative analysis showed differential action of JQ1 on MSCs and NDs. The results showed selective neuronal toxicity of JQ1 in NDs but not in the undifferentiated MSCs. These findings suggest a more careful examination of the selection and use of BET inhibitors as therapeutic agents, as they may cause unwanted damage to non-target cells and tissues.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Oncotarget Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos